The Global Lyo Bead Industry: Market Size, Growth, Applications, Companies & Future Trends

10/8/202615 min read

Introduction
What Are Lyo Beads?
The Current Lyo Bead Market
What the Market Numbers Actually Tell Us
Scientific Evidence Behind Lyo Bead Adoption
Commercial Applications
Food-Safety Diagnostics: A Real Commercial Example
Ready-to-Use PCR Beads
Lyo-Ready Reagent Formulations
Lyo Bead Manufacturing Technology
Equipment and Production Systems
The Broader Molecular Diagnostics Market
Point-of-Care Diagnostics
Regional Opportunity: Asia-Pacific and India
Emerging Applications
Competing Stabilization and Product Formats
Key Industry Challenges
Where the Commercial Opportunity Is
Industry Ecosystem
Future Trends
Frequently Asked Questions
Conclusion
References

1. Introduction

Lyo beads have moved beyond being a laboratory curiosity. They are now represented in commercial diagnostic products, reagent platforms, research applications, specialized manufacturing systems, and an expanding ecosystem of formulation and lyophilization technologies.

However, the size and maturity of the industry require careful interpretation.

Commercial market studies published in 2026 estimate the global lyophilized beaded reagents (LBRs) market at approximately US$226–238 million in 2025, with forecasts of approximately US$496–502 million by 2032. The reported compound annual growth rates are approximately 11.3–12.0%. [1,2]

These figures are useful, but they should not be interpreted as the value of every product that uses lyophilization in a bead, pellet, sphere, or other small solid format. Market definitions vary, and the LBR category is considerably narrower than the overall lyophilization market.

The more important question is therefore not simply how large the market is.

It is:

Where is lyo bead technology creating measurable commercial value, what evidence supports adoption, and where are the strongest opportunities for future development?

2. What Are Lyo Beads?

Lyo beads are discrete, typically spherical units of material that have been frozen and subsequently dried by lyophilization.

In diagnostic and life-science applications, the starting formulation can contain enzymes, primers, probes, nucleotides, buffers, stabilizers, antibodies, antigens, controls, or other functional components.

The manufacturing sequence generally involves:

Formulation → precision dispensing → freezing → lyophilization → handling/packaging → storage → reconstitution

The commercial attraction is not simply the shape.

A bead can provide a defined dose, simplify reagent handling, reduce liquid-pipetting operations, support automation, and potentially enable more convenient shipping and storage.

Commercial market definitions of LBRs specifically describe ready-to-use biological or diagnostic formulations manufactured by precision dispensing, freezing, and vacuum drying into solid bead-shaped units. [1,2]

3. The Current Lyo Bead Market

Two commercial market studies published in 2026 provide useful quantitative evidence for understanding the current scale of the sector.

LP Information estimates the global LBR market at US$226 million in 2025, increasing to US$496 million by 2032, with a reported 12.0% CAGR for 2026–2032. [1]

GlobalInfoResearch estimates the 2025 market at US$238 million, increasing to US$502 million by 2032, corresponding to an 11.3% CAGR over its stated forecast period. [2]

The two estimates are not identical, but they are directionally consistent.

The implied increase from 2025 to 2032 is approximately:

US$270 million in the LP Information forecast.
US$264 million in the GlobalInfoResearch forecast.
Approximately 111–120% growth relative to the respective 2025 market estimates.

This is a meaningful growth rate for a specialized reagent-format market.

At the same time, the estimates should be treated as commercial market-research forecasts rather than audited industry statistics. Both reports are proprietary commercial studies, and their methodologies, company coverage, segmentation, and definitions should be reviewed before using the figures for investment or strategic decisions.

4. What the Market Numbers Actually Tell Us

The most important conclusion from the available market data is not that lyo beads are already a massive industry.

They are not.

The evidence instead suggests that lyo beads represent a small but rapidly expanding technology segment within the much larger molecular diagnostics, life-science reagents, and stabilization markets.

For comparison, MarketsandMarkets estimates the global molecular diagnostics market at approximately US$19.48 billion in 2025, increasing to approximately US$30.74 billion by 2030, at a CAGR of approximately 9.6%. [3]

Against that figure, the estimated 2025 LBR market of approximately US$226–238 million represents roughly 1.2% of the global molecular diagnostics market, or approximately 82–86 times smaller in absolute market value.

This distinction matters.

A growing LBR market does not mean that every molecular diagnostic product will transition to beads. Instead, the opportunity exists where the physical advantages of a discrete dried reagent provide enough value to justify formulation development, manufacturing complexity, packaging requirements, and quality-control costs.

The current evidence therefore supports a high-growth niche rather than a mature mass market.

The 2025 baseline is also important when discussing the post-COVID market. Current commercial forecasts are based on 2025 market conditions rather than the exceptional diagnostic demand observed during the acute COVID-19 period. However, publicly available market summaries do not isolate precisely how much of current LBR growth represents post-pandemic normalization versus structural adoption.

5. Scientific Evidence Behind Lyo Bead Adoption

Commercial forecasts become more meaningful when supported by technical evidence.

A 2021 Talanta study demonstrated freeze-dried PCR reagents formulated as beads for microfluidic molecular diagnostics. The authors reported that PCR components could be pre-mixed, freeze-dried into beads, and transferred into microfluidic chips. Nineteen PCR mixes were investigated, with room-temperature stability reported for 1–2 years under the study conditions. [4]

This demonstrates an important principle:

The bead is not merely a storage format; it can become part of the assay workflow.

A 2026 AAPS Open study compared capillary-assisted vitrification (CAV) with lyophilization for probe qPCR master mixes. The authors describe lyophilization as requiring formulation optimization and relatively long drying cycles, with associated cost implications. In their study, CAV produced comparable performance and stability to the lyophilized comparator under the tested conditions, while using a shorter stabilization process. [5]

This is important because lyo beads do not compete only with liquid reagents.

They also compete with other stabilization technologies.

A 2023 study in Antibiotics further demonstrated lyophilized reagent beads in a multiphase, single-vessel assay for rapid minimum inhibitory concentration analysis. The system incorporated lyophilized reagent components into an integrated diagnostic workflow. [6]

Together, these studies show three different levels of evidence: technical feasibility, comparison with an alternative stabilization approach, and integration into a more complex diagnostic workflow.

6. Commercial Applications

Current and emerging applications include:

Molecular diagnostics

PCR and qPCR reagents are among the most technically established applications. A bead can contain a pre-defined quantity of amplification reagents, reducing manual preparation.

Point-of-care diagnostics

Lyo beads can support decentralized testing by reducing cold-chain dependence and simplifying reagent handling.

Food-safety testing

Commercial pathogen-detection assays demonstrate that the format has moved into regulated analytical workflows.

Research reagents

Ready-to-use PCR beads and other stabilized reagents can simplify routine molecular biology workflows.

Veterinary and agricultural diagnostics

Lyophilized bead technology is also relevant to veterinary, agricultural, environmental, and field-based testing. New England Biolabs specifically discusses applications extending beyond conventional laboratory diagnostics, including veterinary and agricultural testing. [7]

Multiplex and integrated assays

As assay complexity increases, individually controlled dried reagent units may provide opportunities for more automated reagent assembly.

7. Food-Safety Diagnostics: A Real Commercial Example

One of the clearest current examples is the Applied Biosystems MicroSEQ™ Listeria monocytogenes Detection Kit.

Thermo Fisher Scientific states that the kit's reagents are lyophilized into preformatted assay beads. The beads contain the active enzyme, target-specific primer and probe set, internal positive control, and other PCR reagents. The company also states that the complete workflow has been validated by the AOAC Research Institute. [8]

This is important because it provides evidence at a different level from a research paper.

It demonstrates that lyophilized bead technology can exist inside a commercial, validated analytical workflow rather than only inside laboratory research.

The distinction between research feasibility and commercial implementation is critical when evaluating the maturity of the industry.

8. Ready-to-Use PCR Beads

Another long-running example is Cytiva PuReTaq Ready-To-Go™ PCR Beads.

Current Fisher Scientific listings identify the product as pre-mixed and pre-dispensed reaction beads for standard PCR amplification. The listings describe ambient-temperature-stable beads and provide multiple formats, including 0.2 mL and 0.5 mL formats. [9]

The product demonstrates another important commercial value proposition:

standardization of a repetitive reagent-preparation step.

Instead of preparing the PCR reaction mixture manually, the user works with a predefined reagent unit and adds the required assay components.

This can reduce pipetting operations and improve workflow consistency.

The product should not, however, be interpreted as evidence that every type of PCR or RT-PCR reagent has been commercialized successfully in bead form. Its evidence is specific to the product and application.

9. Lyo-Ready Reagent Formulations

Not every company participating in the lyo-reagent ecosystem manufactures finished beads.

Meridian Bioscience, for example, offers Lyo-Ready™ qPCR/RT-qPCR and LAMP/RT-LAMP formulations designed to withstand freeze-drying and support development of ambient-temperature-stable molecular assays. [10]

This represents an important distinction within the industry:

the lyo bead ecosystem includes both bead manufacturers and companies supplying formulations intended to become lyophilized products.

That creates opportunities across formulation science, excipient development, assay development, process development, and contract manufacturing.

10. Lyo Bead Manufacturing Technology

The manufacturing process introduces challenges that do not exist to the same extent with conventional vial-based lyophilization.

The formulation must first be converted into discrete droplets or units with sufficiently controlled volume.

The droplets then need to be frozen consistently.

During lyophilization, heat and mass transfer must be controlled while maintaining the required physical structure and biological activity.

After drying, the beads must survive:

handling,
transfer,
packaging,
transportation,
storage,
and reconstitution.

Important development variables therefore include formulation composition, droplet volume, freezing conditions, product temperature, chamber pressure, shelf temperature, residual moisture, bead mechanical strength, reconstitution behavior, and assay performance.

The small dimensions of a bead can provide favorable surface-area-to-volume characteristics for reconstitution and heat/mass-transfer behavior, but this does not eliminate the need for formulation- and product-specific cycle development.

11. Equipment and Production Systems

Dedicated manufacturing systems are emerging around lyo bead production.

Millrock Technology currently describes a turnkey LyoBead production system incorporating a BeadLab™ dispenser, sealable tray, and freeze dryer. [11]

The company's current LyoBead page describes beads in the 5–20 µL range. [11]

A Millrock production-system document revised in June 2022 describes a four-head BeadLab micro-dispensing system capable of producing approximately 4 beads per second in 5–20 µL bead volumes. The same document lists approximate batch capacities of 80,000, 112,000, 224,000, and 280,000 beads, depending on the freeze-dryer configuration. It also states an expected drying time of approximately 12 hours. [12]

A separate Millrock document revised January 19, 2023 gives updated production specifications. It lists approximate batch capacities of 80,000–280,000 beads for the same range of freeze-dryer configurations and states 6,000+ to 18,000+ beads/hour for the listed configurations, while noting that each BeadLab can produce 8,000+ beads/hour and that throughput may vary with bead size and pump size. [13]

These documents are not independent production benchmarks. They are manufacturer specifications, and they should be interpreted according to the dated configuration and conditions under which they were published.

Applyo Jena provides another example of specialized bead-production technology. Its current technology page states that its system can produce 120,000 Applyo Beads per batch and day, while the company reports having demonstrated 400,000 beads per batch and is developing a future system targeting substantially higher throughput. These are company-reported capabilities rather than independent industry benchmarks. [14]

The emergence of dedicated equipment is significant because it indicates that manufacturers are beginning to treat bead production as a specialized manufacturing problem rather than simply adapting conventional vial lyophilization.

12. The Broader Molecular Diagnostics Market

The commercial opportunity for lyo beads cannot be separated from the market in which many of their applications operate.

MarketsandMarkets estimates the global molecular diagnostics market at approximately US$19.48 billion in 2025, increasing to approximately US$30.74 billion by 2030, representing a 9.6% CAGR. [3]

The market includes reagents and kits, instruments, software, laboratory testing, point-of-care testing, PCR, isothermal amplification, sequencing, and other technologies.

Lyo beads therefore do not need to capture a large percentage of the entire molecular diagnostics market to become commercially meaningful.

A small share of a large downstream market can support a specialized technology ecosystem.

13. Point-of-Care Diagnostics

The point-of-care segment is particularly relevant because decentralized testing increases the value of simplified reagent logistics.

MarketsandMarkets estimates the global point-of-care molecular diagnostics market at approximately US$4.30 billion in 2025, increasing to approximately US$7.09 billion by 2030, with a 10.5% CAGR. [15]

The relationship with lyo beads is indirect.

The market growth does not prove that lyo beads will be the preferred stabilization technology.

It does, however, identify a downstream environment in which technologies offering simplified storage, transport, dosing, and reconstitution can have strategic value.

14. Regional Opportunity: Asia-Pacific and India

Asia-Pacific is an important downstream market for molecular diagnostics. A 2026 MarketsandMarkets regional analysis estimates the Asia-Pacific molecular diagnostics market at US$3.85 billion in 2025, reaching US$7.58 billion by 2031, with a reported 12.4% CAGR from 2026 to 2031. The report identifies diagnostic laboratories as the largest end-user segment in 2025 and states that India is expected to register the highest CAGR within the Asia-Pacific market. [16]

India provides an especially interesting market context.

MarketsandMarkets estimates India's molecular diagnostics market at approximately US$262.3 million in 2025, reaching approximately US$510.6 million by 2030, with a reported 14.3% CAGR. The report's segmentation shows diagnostic laboratories as a major end-user segment, with a 2025 value of approximately US$247.2 million in its end-user table. [17]

These figures do not mean that India or Asia-Pacific has an equivalent lyo bead market.

Rather, they indicate rapidly expanding downstream diagnostics environments in which stabilized reagent formats may have commercial relevance.

For manufacturers and technology developers, the opportunity may therefore exist in areas such as:

reagent localization,
ambient-temperature-stable assays,
decentralized testing,
contract manufacturing,
assay development,
reagent formulation,
and cost-efficient high-volume production.

15. Emerging Applications

Several areas deserve continued technical attention.

LAMP and isothermal amplification

LAMP is particularly compatible with decentralized workflows because amplification can be performed without the thermal cycling requirements of conventional PCR.

Lyo-ready LAMP formulations are already commercially available, although the availability of a lyo-ready formulation is not equivalent to widespread adoption of a finished bead format. [10]

Multiplex diagnostics

Multiplex assays increase formulation complexity because several biological and chemical components must remain compatible throughout freezing and drying.

Antimicrobial susceptibility testing

The 2023 MIC study demonstrates the possibility of integrating different lyophilized reagent units into a more complex assay workflow. [6]

Integrated diagnostic cartridges

Closed-cartridge platforms such as Cepheid's GeneXpert demonstrate the broader market movement toward automated sample-to-answer diagnostics. GeneXpert uses closed-cartridge technology and integrates sample extraction, PCR amplification, and detection. [18]

This does not establish that GeneXpert uses lyo beads internally. Instead, it demonstrates the downstream market trend toward increasingly integrated diagnostic workflows in which stabilized, preconfigured reagents can be commercially valuable.

16. Competing Stabilization and Product Formats

Lyo beads are not competing against only conventional liquid reagents.

The competitive landscape includes:

liquid refrigerated reagents,
lyophilized cakes,
dried pellets,
tablets,
capillary-assisted vitrification,
other dry-stabilization technologies,
and fully integrated cartridge systems.

The choice depends on the assay.

A bead may be attractive when discrete dosing, automated handling, rapid reconstitution, or integration into a cartridge provides measurable value.

A conventional cake may be more appropriate where high-volume material is reconstituted as a bulk solution.

The 2026 AAPS Open comparison with capillary-assisted vitrification illustrates why technology selection should be based on the entire manufacturing and performance profile rather than assuming that lyophilization is automatically the best stabilization method. [5]

17. Key Industry Challenges

The major barriers to wider adoption are technical as well as economic.

Formulation stability

Biological reagents can respond differently to freezing, dehydration, residual moisture, oxygen exposure, and storage temperature.

Bead uniformity

Variation in droplet volume can translate directly into dose variation.

Mechanical robustness

A bead that performs well analytically but breaks during automated handling or transportation is not commercially robust.

Process scale-up

Increasing throughput can change freezing behavior, thermal loads, tray configuration, chamber utilization, and cycle performance.

Packaging

The final package must protect against moisture and environmental exposure while remaining compatible with automated assembly.

Cost

Dedicated dispensing, handling, lyophilization, packaging, and quality-control operations can make bead production more expensive than liquid formulations unless the downstream workflow gains offset the additional manufacturing cost.

Regulatory evidence

For diagnostic products, analytical performance, stability, manufacturing consistency, and regulatory requirements must be demonstrated for the final commercial configuration.

18. Where the Commercial Opportunity Is

The available evidence suggests that the strongest opportunities are unlikely to come from simply producing generic “lyo beads.”

The more defensible opportunities are tied to specific workflow problems.

Examples include:

Ambient-stable molecular assays: where eliminating or reducing cold-chain requirements provides measurable logistical value.

Ready-to-use diagnostic reagents: where reducing manual preparation improves workflow consistency.

Automated assay assembly: where discrete reagent units can be integrated into cartridges or automated platforms.

Specialized contract development and manufacturing: where diagnostic companies require formulation, bead production, lyophilization, packaging, and scale-up expertise.

High-throughput bead manufacturing: where equipment and process technology can reduce cost per reaction.

Advanced formulation platforms: where stabilizing difficult biological components becomes a differentiating capability.

The commercial opportunity therefore sits at the intersection of formulation science, manufacturing engineering, diagnostics, automation, and supply-chain economics.

19. Industry Ecosystem

The emerging ecosystem can be divided into several groups.

Reagent and assay companies develop enzymes, master mixes, molecular assays, and diagnostic products.

Lyophilization technology providers develop formulation and process expertise.

Bead-production technology companies develop dispensing, freezing, transfer, tray, and freeze-drying systems.

Diagnostic manufacturers integrate stabilized reagents into commercial workflows.

CDMOs and specialized manufacturers can provide formulation development, process development, manufacturing, and packaging capabilities.

Examples of companies active in these areas include Cytiva, Thermo Fisher Scientific, Meridian Bioscience, Evik Diagnostics, Biopharma Group, Applyo Jena, and Millrock Technology. The roles differ: some supply reagents or assays, some provide bead or lyophilization technology, and others provide development or manufacturing services. [8–14,19,20]

Evik Diagnostics, for example, currently describes contract development and manufacturing of single- and multiplex-assay lyophilized beads and identifies an ISO 13485:2016-certified manufacturing scope for lyophilized reagent beads. [19]

Biopharma Group also describes lyobead production services and a broader diagnostic CDMO capability that includes freeze-drying and lyobead technology. [20]

This ecosystem is important because the future industry is unlikely to be dominated by a single type of company.

20. Future Trends

Several trends are likely to shape the sector.

1. Higher-throughput manufacturing

As demand increases, throughput and cost per bead will become increasingly important.

2. Greater automation

Automated dispensing, transfer, inspection, packaging, and assembly will reduce dependence on manual handling.

3. More complex formulations

Multiplex assays and integrated workflows will increase formulation-development requirements.

4. Decentralized diagnostics

The continued expansion of point-of-care molecular diagnostics creates downstream demand for simplified reagent formats. [15]

5. Alternative stabilization technologies

Lyo beads will increasingly be compared with vitrification and other stabilization approaches based on total process economics and performance rather than storage stability alone. [5]

6. Integration with automated platforms

The greatest value may increasingly come from the combination of the bead with the diagnostic instrument, cartridge, software, and workflow rather than from the bead itself.

7. Specialized manufacturing infrastructure

Dedicated bead-production equipment such as the systems described by Millrock and Applyo indicates increasing specialization of the manufacturing ecosystem. [11–14]

21. Frequently Asked Questions

Is the global lyo bead market already large?
No. Available 2026 commercial estimates place the LBR market at approximately US$226–238 million in 2025. The market is small relative to molecular diagnostics overall, but the reported growth rate is comparatively high. [1,2]

Are lyo beads used commercially?
Yes. Commercial examples include Applied Biosystems MicroSEQ Listeria monocytogenes assay beads and Cytiva PuReTaq Ready-To-Go™ PCR Beads. [8,9]

Are lyo beads used only for diagnostics?
No. Research applications, molecular biology workflows, veterinary and agricultural testing, food safety, and other stabilized reagent applications are also relevant. [7]

Are all lyophilized reagents lyo beads?
No. Lyophilized products can exist as cakes, pellets, beads, or other geometries. The manufacturing format and downstream workflow matter.

Are lyo beads automatically better than liquid reagents?
No. They can provide advantages in dosing, storage, handling, and workflow integration, but these benefits must be weighed against formulation complexity, process development, manufacturing cost, and packaging requirements.

Are lyo beads the same as PCR beads?
Not necessarily. PCR beads are one application category within the broader class of lyophilized reagent beads.

22. Conclusion

The global lyo bead industry is best understood as a rapidly developing specialist segment within the broader life-science reagent and molecular diagnostics markets.

The strongest quantitative evidence currently available places the global LBR market at roughly US$226–238 million in 2025, with forecasts approaching US$500 million by 2032. [1,2]

Scientific publications demonstrate that bead-based lyophilization can support molecular assays, microfluidic diagnostics, and integrated workflows. Commercial products demonstrate that the technology has already reached real-world analytical applications. [4,6,8,9]

At the same time, the industry is not yet mature enough to assume universal adoption.

The major commercial question is whether the advantages of a discrete lyophilized reagent—standardized dosing, simplified handling, stability, portability, and automation—can outweigh the additional requirements for formulation development, specialized manufacturing, quality control, and packaging.

That is where the next stage of lyo bead development is likely to be decided.

23. References

[1] LP Information. Global Lyophilized Beaded Reagents (LBRs) Market Growth (Status and Outlook) 2026–2032. Published July 2, 2026. Commercial market research report. Accessed October 8, 2026. LP Information — LBR Market Report

[2] GlobalInfoResearch. Global Lyophilized Beaded Reagents (LBRs) Market 2026 by Company, Regions, Type and Application, Forecast to 2032. Published July 17, 2026. Commercial market research report. Accessed October 8, 2026. GlobalInfoResearch — LBR Market Report

[3] MarketsandMarkets. Molecular Diagnostics Market by Product & Service, Test Type, Technology, Application and Region — Global Forecast to 2030. 2025 edition/current market information. Accessed October 8, 2026. MarketsandMarkets — Molecular Diagnostics Market

[4] Xu J, Wang J, Su X, et al. Transferable, easy-to-use and room-temperature-storable PCR mixes for microfluidic molecular diagnostics. Talanta. 2021;235:122797. doi:10.1016/j.talanta.2021.122797. DOI / Full Article

[5] Renu S, Peris-Taverner Y, Sharpe J, Carroll M, Shank-Retzlaff M, Bronsart L, Mohanty P. Stability and performance comparison of capillary-assisted vitrification and lyophilization for probe qPCR master mixes. AAPS Open. 2026;12:3. Published January 12, 2026. doi:10.1186/s41120-025-00137-z. AAPS Open — Full Article

[6] Khire TS, Gao W, Bales B, et al. Rapid Minimum Inhibitory Concentration (MIC) Analysis Using Lyophilized Reagent Beads in a Novel Multiphase, Single-Vessel Assay. Antibiotics. 2023;12(11):1641. doi:10.3390/antibiotics12111641. MDPI — Antibiotics Article / DOI

[7] Gibson J. How Lyophilized Beads Are Changing Diagnostics and Research. NEBinspired, New England Biolabs. Published June 22, 2025. Accessed October 8, 2026. NEB — How Lyophilized Beads Are Changing Diagnostics and Research

[8] Thermo Fisher Scientific / Applied Biosystems. MicroSEQ™ Listeria monocytogenes Detection Kit. Current product information. Accessed October 8, 2026. Thermo Fisher Scientific — MicroSEQ Listeria Detection Kit

[9] Cytiva / Fisher Scientific. Cytiva PuReTaq Ready-To-Go™ PCR Beads. Current product listings and specifications. Accessed October 8, 2026. Fisher Scientific — Cytiva PuReTaq Ready-To-Go PCR Beads

[10] Meridian Bioscience. Lyo-Ready™ qPCR/RT-qPCR and LAMP/RT-LAMP Reagent Products. Current product information. Accessed October 8, 2026.

[11] Millrock Technology, Inc. LyoBead Production Systems. Current LyoBead/BeadLab™ product information. Accessed October 8, 2026. Millrock Technology — LyoBead Production Systems

[12] Millrock Technology, Inc. LyoBead Production Systems. Production-system specification, revised June 2022. Accessed October 8, 2026. Millrock Technology — June 2022 LyoBead Production Systems PDF

[13] Millrock Technology, Inc. LyoBead Production Systems. Production-system specification, revised January 19, 2023. Accessed October 8, 2026. Millrock Technology — January 19, 2023 LyoBead Production Systems PDF

[14] Applyo Jena. Our Technology: Freeze-Dried Applyo Beads and Proprietary Freeze-Drying Technology. Current technology information. Accessed October 8, 2026. Applyo Jena — Our Technology

[15] MarketsandMarkets. Point-of-Care Molecular Diagnostics Market — Global Forecast to 2030. 2025 edition/current market information. Accessed October 8, 2026. MarketsandMarkets — Point-of-Care Molecular Diagnostics Market

[16] MarketsandMarkets. Asia Pacific Molecular Diagnostics Market Size, Growth, Share & Trends Analysis — Forecast to 2031. Published October 2026. Accessed October 8, 2026. MarketsandMarkets — Asia Pacific Molecular Diagnostics Market

[17] MarketsandMarkets. India Molecular Diagnostics Market, 2025–2030. Published July 2026. Accessed October 8, 2026. MarketsandMarkets — India Molecular Diagnostics Market

[18] Cepheid. GeneXpert® System with Touchscreen. Current product information. Accessed October 8, 2026. Cepheid — GeneXpert System with Touchscreen

[19] Evik Diagnostics. Lyobeads Contract Manufacturing. Current company and manufacturing information. Accessed October 8, 2026. Evik Diagnostics — Lyobeads Contract Manufacturing

[20] Biopharma Group. Diagnostics Manufacturing / Lyobead Technology. Current CDMO and manufacturing information. Accessed October 8, 2026.

Educational Disclaimer

This article is intended solely for educational purposes. Lyo bead formulation development, process development, manufacturing, analytical testing, validation, and commercialization should always be performed in accordance with applicable GMP requirements, regulatory guidance, validated procedures, organizational procedures, and qualified scientific and engineering judgment.